2023-07-01 2024-06-30 false Capium Accounts Production 1.1 14153165 2023-07-01 2024-06-30 14153165 bus:AbridgedAccounts 2023-07-01 2024-06-30 14153165 bus:FRS102 2023-07-01 2024-06-30 14153165 bus:AuditExemptWithAccountantsReport 2023-07-01 2024-06-30 14153165 bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 14153165 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 14153165 2023-07-01 2024-06-30 14153165 2024-06-30 14153165 bus:RegisteredOffice 2023-07-01 2024-06-30 14153165 core:WithinOneYear 2024-06-30 14153165 core:AfterOneYear 2024-06-30 14153165 1 2023-07-01 2024-06-30 14153165 bus:Director1 2023-07-01 2024-06-30 14153165 bus:Director1 2024-06-30 14153165 bus:Director1 2022-07-01 2023-06-30 14153165 bus:Director2 2023-07-01 2024-06-30 14153165 bus:Director2 2024-06-30 14153165 bus:Director2 2022-07-01 2023-06-30 14153165 2022-07-01 14153165 bus:LeadAgentIfApplicable 2023-07-01 2024-06-30 14153165 2022-07-01 2023-06-30 14153165 2023-06-30 14153165 core:WithinOneYear 2023-06-30 14153165 core:AfterOneYear 2023-06-30 14153165 bus:EntityAccountantsOrAuditors 2022-07-01 2023-06-30 14153165 bus:OrdinaryShareClass1 2023-07-01 2024-06-30 14153165 bus:OrdinaryShareClass1 2024-06-30 14153165 bus:OrdinaryShareClass1 2022-07-01 2023-06-30 14153165 bus:OrdinaryShareClass1 2023-06-30 14153165 core:ComputerEquipment 2023-07-01 2024-06-30 14153165 core:ComputerEquipment 2024-06-30 14153165 core:ComputerEquipment 2023-06-30 14153165 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-06-30 14153165 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-06-30 14153165 core:CostValuation core:Non-currentFinancialInstruments 2024-06-30 14153165 core:CostValuation core:Non-currentFinancialInstruments 2023-06-30 14153165 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-06-30 14153165 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-06-30 14153165 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-06-30 14153165 core:Non-currentFinancialInstruments 2024-06-30 14153165 core:Non-currentFinancialInstruments 2023-06-30 14153165 core:ShareCapital 2024-06-30 14153165 core:ShareCapital 2023-06-30 14153165 core:RetainedEarningsAccumulatedLosses 2024-06-30 14153165 core:RetainedEarningsAccumulatedLosses 2023-06-30 14153165 dpl:Item1 2023-07-01 14153165 dpl:Item1 2024-06-30 14153165 dpl:Item1 2022-07-01 14153165 dpl:Item1 2023-06-30 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 14153165
England and Wales

 

 

 

ASP3NCER MEDICAL IMAGING LTD


Abridged Accounts
 


Period of accounts

Start date: 01 July 2023

End date: 30 June 2024
Report to the directors on the preparation of the unaudited statutory accounts of ASP3NCER MEDICAL IMAGING LTD for the year ended 30 June 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of ASP3NCER MEDICAL IMAGING LTD for the year ended 30 June 2024 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company’s accounting records and from information and explanations you have given us
As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at
http://rulebook.accaglobal.com/
This report is made solely to the Board of Directors of ASP3NCER MEDICAL IMAGING LTD, as a body, in accordance with the terms of our engagement letter dated 02 April 2025 Our work has been undertaken solely to prepare for your approval the accounts of ASP3NCER MEDICAL IMAGING LTD and state those matters that we have agreed to state to the Board of Directors of ASP3NCER MEDICAL IMAGING LTD, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/factsheet163. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than ASP3NCER MEDICAL IMAGING LTD and its Board of Directors as a body for our work or for this report.
It is your duty to ensure that ASP3NCER MEDICAL IMAGING LTD has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of ASP3NCER MEDICAL IMAGING LTD. You consider that ASP3NCER MEDICAL IMAGING LTD is exempt from the statutory audit requirement for the year
We have not been instructed to carry out an audit or a review of the accounts of ASP3NCER MEDICAL IMAGING LTD. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts
30 June 2024



....................................................
J and Co. Accountants
85 Great Portland Street,,W1W 7LT
First Floor
LONDON
United Kingdom
W1W 7LT
02 April 2025
1
 
 
Notes
 
2024
£
  2023
£
Fixed assets      
Tangible fixed assets 3 4,188   
4,188   
Current assets      
Cash at bank and in hand 24,697    14,847 
Creditors: amount falling due within one year (11,579)   (14,470)
Net current assets 13,118    377 
 
Total assets less current liabilities 17,306    377 
Accruals and deferred income (1,000)  
Net assets 16,306    377 
 

Capital and reserves
     
Called up share capital 4 2    2 
Profit and loss account 16,304    375 
Shareholders' funds 16,306    377 
 


For the year ended 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the board of directors on 02 April 2025 and were signed on its behalf by:


-------------------------------
Akpan SPENCER
Director
2
General Information
ASP3NCER MEDICAL IMAGING LTD is a private company, limited by shares, registered in England and Wales, registration number 14153165, registration address 85 GREAT PORTLAND STREET, FIRST FLOOR LONDON, W1W 7LT.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Computer Equipment 25% Reducing Balance
2.

Average number of employees

Average number of employees during the year was 1 (2023 : 1).
3.

Tangible fixed assets

Cost or valuation Computer Equipment   Total
  £   £
At 01 July 2023  
Additions 5,584    5,584 
Disposals  
At 30 June 2024 5,584    5,584 
Depreciation
At 01 July 2023  
Charge for year 1,396    1,396 
On disposals  
At 30 June 2024 1,396    1,396 
Net book values
Closing balance as at 30 June 2024 4,188    4,188 
Opening balance as at 01 July 2023  


4.

Share Capital

Allotted, called up and fully paid
2024
£
  2023
£
2 Class A shares of £1.00 each  
 

3